WO1997009998A2 - Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors - Google Patents
Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors Download PDFInfo
- Publication number
- WO1997009998A2 WO1997009998A2 PCT/US1996/014623 US9614623W WO9709998A2 WO 1997009998 A2 WO1997009998 A2 WO 1997009998A2 US 9614623 W US9614623 W US 9614623W WO 9709998 A2 WO9709998 A2 WO 9709998A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igf
- expression
- related tumors
- test substance
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 title description 89
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 title description 78
- 238000000034 method Methods 0.000 claims abstract description 60
- 230000014509 gene expression Effects 0.000 claims abstract description 43
- 238000009739 binding Methods 0.000 claims abstract description 29
- 230000027455 binding Effects 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 239000002773 nucleotide Substances 0.000 claims abstract description 17
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 17
- 239000013604 expression vector Substances 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 9
- 230000001939 inductive effect Effects 0.000 claims abstract description 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 7
- 239000002254 cytotoxic agent Substances 0.000 claims abstract description 7
- 231100000599 cytotoxic agent Toxicity 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 239000000411 inducer Substances 0.000 claims abstract description 5
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims abstract description 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims abstract description 3
- 239000003623 enhancer Substances 0.000 claims abstract description 3
- 230000000977 initiatory effect Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 63
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 30
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 22
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 16
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 16
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 15
- 230000006820 DNA synthesis Effects 0.000 claims description 12
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 9
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 9
- 108700008625 Reporter Genes Proteins 0.000 claims description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims 1
- 102000038460 IGF Type 2 Receptor Human genes 0.000 claims 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 73
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 72
- 108020004414 DNA Proteins 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 10
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000002297 mitogenic effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 3
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 241000282320 Panthera leo Species 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000003305 autocrine Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 230000003076 paracrine Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000004565 tumor cell growth Effects 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 2
- 239000012623 DNA damaging agent Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 231100000024 genotoxic Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229940127084 other anti-cancer agent Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000016596 traversing start control point of mitotic cell cycle Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- NDJNDUULNXNRQD-XKBRQERYSA-N 1-[(2r,4s,5s)-5-[bromo(hydroxy)methyl]-4-hydroxyoxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](C(Br)O)O[C@H]1N1C(=O)NC(=O)C=C1 NDJNDUULNXNRQD-XKBRQERYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- JJDLLVZMTMEVBY-DAXSKMNVSA-N BOX B Chemical compound CC1=C(C=C)C(=O)N\C1=C/C(N)=O JJDLLVZMTMEVBY-DAXSKMNVSA-N 0.000 description 1
- 101150070257 BPS gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000054184 GADD45 Human genes 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 238000003318 immunodepletion Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229940090004 megace Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- -1 β-chloroethyl Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to methods of using a protein designated IGF-BP3, which affects apoptosis and tumor suppression.
- This invention also relates to methods of identifying and using modulators and mimetics of IGF-BP3.
- p53 is a tumor suppressor well known in the art. Upregulation and activation of p53 are an important cellular response to genotoxic stress and deregulated expression of certain oncogenes. Hartwell et aL (1994), Science 266: 1821-8. Accordingly, p53 is required for cell cycle arrest at the G1 checkpoint. Hartwell et a (1994); Kuerbitz et al. (1992), Proc. Natl. Acad. Sci USA 89: 7491-5: Kastan et al.
- p53 might also be required as a link to apoptosis in response to E1 A and c-myc oncoprotein expression.
- the tumor suppressor function of p53 is thought to be mediated, at least in part, by its ability to act as a sequence-specific transcriptional activator.
- Genes such as p21/WAF1 (El-Deiry et aL (1993), Cell 75: 817-25) and GADD45 (Kastan et aj. (1992). Cell 71 : 587-97) are p53-regulated target genes. These genes encode proteins that directly interact with components of the cell cycle and DNA replication machinery and provide a direct link between the p53-dependent G1 checkpoint in the cell cycle, DNA repair and cellular proliferation. Harper et a (1993), £e_ 75: 805-16; Xiong, et aL (1993), Nature 366: 701-4; Smith et aL (1994), Science 266: 1376-80.
- IGF-I and -II insulin-like growth factors
- IGF-I and to some extent IGF-II
- IGF-I is a mitogen that stimulates cellular proliferation (associated with elevated cyclin D1 and cdc2) and transformation. More recently, studies suggest that IGF-I acts as a survival factor, protecting cells from undergoing apoptosis (cell death). Sell, C. ej aj. (1995), Cancer Research 55: 303-6. This latter activity may be particularly important in promoting tumor cell growth. Animal studies clearly suggest a role for IGF-I and IGF-IR in tumor growth.
- IGF-BP3 insulin-like growth factor binding protein-3 regulates the IGF-IGFR axis.
- Cubbage and colleagues recently described 8.9 kb of genomic sequence, including the promoter and 1.9 kb of 5' flanking sequence, five exons, four introns and approximately 1.5 kb of 3' flanking sequence for the IGF-BP3 gene.
- IGF-BP3 in combination with IGF for treatment of catabolic conditions (e.g., burns, trauma, peptic ulcers).
- catabolic conditions e.g., burns, trauma, peptic ulcers.
- IGF-BP3 intemational Patent Application WO 9404030.
- the art does not describe, however, any link between the IGF-binding activity of IGF-BP3 and the tumor suppressor p53.
- the present invention concerns methods of treating p53-related tumors.
- p53-related refers to tumor cells in which wild-type (wt) p53 is absent, disabled or otherwise mutated.
- These methods of treatment comprise administering an effective amount of either (1) a modulator of IGF-BP3, (2) IGF-BP3 itself, or (3) an expression vector comprising a nucleotide sequence encoding IGF-BP3.
- the modulator upregulates IGF-BP3 expression or activity.
- one may also operatively link the IGF-BP3 nucleotide sequence to an inducible promoter or enhancer, and the method further comprises administering an inducer capable of initiating or upregulating expression of the protein.
- any of the foregoing methods may include as an additional step administration of a cytotoxic agent, as the present inventors believe that IGF-BP3 can make tumor cells more susceptible to such agents.
- the invention further concerns methods of identifying substances useful in treatment of p53-related tumors.
- One such method uses a reporter gene operatively linked to the p53-responsive elements described below, wherein expression of the reporter signals upregulation of IGF-BP3.
- Another such method employs a cancer cell having IGF-I or -II receptors in the presence of bases or nucleotides having a detectable label, wherein a decrease in uptake of the label signals a decrease in IGF-directed DNA synthesis.
- Figure 1 a-d shows the regulation of IGF-BP3 gene expression by wild type p53.
- Figure 1a shows the genomic structure of the IGF-BP3 gene indicating the map location (nucleotides 8095-8452) and nucleotide sequence (SEQ. ID. NO.: 1) of the cDNA fragment, probe V9.
- Figure 1b shows a comparative northern blot analysis of p53-induced IGF-BP3 mRNA expression in CdU2-act ⁇ vated EB-1 cells.
- Figure 1c a temperature-sensitive mutant of p53 (p53V143A) induces expression of IGF-BP3 mRNA in the clonal Saos-2-D4H cells described in Buckbinder et aL (1994), Proc. Natl. Acad. Sci. USA 91: 10640-4.
- Figure Id shows kinetic analysis of p53-reguiated transcript expression in CdCl2-activated EB-1 cells.
- Figure 2 shows characterization of p53-binding and p53-responsive DNA elements in the IGF-BP3 gene.
- Figure 2a shows two sequences (SEQ. ID. NOS.: 2 and 3) in the published IGF-BP3 gene structure that we determined by computer analysis to have similarity to the p53 consensus binding site (RRRCWWGYYY)2 (SEQ. ID. NO.: 4). These sequences are denoted here Box A (SEQ. ID. NO.: 2) and Box B (SEQ. ID. NO.: 3) and appear in the first and second introns, respectively.
- Figure 2b shows specific binding of p53 to Box A and B DNA.
- Box A and B DNAs confer p53-inducibility to a heterologous promoter.
- Figure 3 shows inhibition of IGF-I induced DNA synthesis in Saos-2 cells by IGF-BP3.
- Part A shows secretion of IGF-BP3 by induced EB1 cells.
- Part B shows that Saos-2 cells are sensitive to mitogenic IGF-I activity.
- Part C shows that p53- induced IGF-BP3 secreted from EB1 cells inhibits IGF-I mitogenic activity.
- Figure 4a shows expression of IGF-BP3 mRNA in human tissues.
- Figure 4b shows a working model linking p53 to IGF-regulated signaling pathways.
- Figure 5a shows induction of IGF-BP3 by DNA damaging agents.
- Figure 5b shows that induction of IGF-BP3 by DNA damaging agents is dependent on p53.
- p53-responsive DNA elements reside in the first and second introns of the IGF-BP3 gene; (2) wild type but not mutant p53 induces the IGF- BP3 gene; and (3) this response is associated with an increase in both synthesis and secretion of IGF-BP3 into the extracellular space.
- IGF-BP3 binds IGFs and prevents interaction with their IGFRs, thus acting as a growth inhibitor. Furthermore, IGF-BP3 may have growth-inhibitory effects not related to its ability to interact with the IGFs, but rather mediated by an IGFR- independent signaling pathway. Thus, IGF-BP3 may be linked to two distinct signaling pathways associated with cellular growth inhibition.
- the present discovery suggests that one can treat human tumors, in particular those with p53 mutations, by increasing or mimicking IGF-BP3 functions
- This method can employ modulators of IGF-BP3, which one can identify by methods described herein.
- modulators upregulate IGF-BP3 expression or activity.
- One type of such modulators binds to one or both of IGF-BP3's p53-respons ⁇ ve elements (Boxes A and B; SEQ. ID. NOS.. 2 and 3, respectively).
- Another method employs IGF-BP3 protein itself.
- one administers IGF-BP3 protein or recombinant protein (e.g., as supplied by UBI).
- IGF-BP3 protein or recombinant protein e.g., as supplied by UBI.
- one produces, purifies, and formulates the protein for administration by methods known in the art (e.g. Tressel, T. J. et aL (1991), Biochem. Biophvs. Res. Commun. 178: 625-33).
- Still another method of treatment employs an expression vector comprising a nucleotide sequence encoding IGF-BP3.
- Suitable expression vectors include plasmids, but this invention includes other forms of expression vectors that now exist or become known in the art subsequently hereto.
- a useful expression vector typically contains an origin of replication, a promoter upstream from the coding sequence a transcription termination sequence.
- the expression vector may also include other DNA sequences known in the art, such as: stability leader sequences, which stabilize the expression product; secretory leader sequences, which enable secretion of the expression product; environmental feedback sequences, which enable modulation of expression (e.g., by the presence or absence of nutrients or other inducers in the growth medium; marker sequences, which enable phenotypic selection in transformed host cells; restriction sites, which enable cleavage by restriction endonucleases; and sequences that enable expression in various types of hosts, including prokaryotes, yeasts, fungi, plants and higher eukaryotes.
- stability leader sequences which stabilize the expression product
- secretory leader sequences which enable secretion of the expression product
- environmental feedback sequences which enable modulation of expression (e.g., by the presence or absence of nutrients or other inducers in the growth medium
- marker sequences which enable phenotypic selection in transformed host cells
- restriction sites which enable cleavage by restriction endonucleases
- the cloning/expression vector directs the replication and expression, of the nucleic acids of the present invention.
- Suitable origins of replication include, for example, the Col E1, the SV40 viral and the M13 origins of replication.
- Suitable promoters include, for example, the cytomegalovirus promoter, the __Z promoter, the cjaMO promoter and the Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) polyhedral promoter.
- Suitable termination sequences include, for example, the bovine growth hormone, SV40, JacZ and AcMNPV polyhedral polyadenylation signals. Examples of selectable markers include neomycin, ampicillin, and hygromycin resistance and the like All of these materials are known in the art and are commercially available.
- vectors having the foregoing features can be constructed by recombinant DNA techniques known in the art See Sambrook et aj , Molecular Cloning A . Laboratory Manual. Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989). Alternatively, they can use commercially available vectors that already incorporate these features. Suitable commercially available vectors include the baculovirus expression vector pBlueBac, the prokaryotic expression vector pcDNAII and the yeast expression vector pYes2 (Invitrogen Corp., San Diego, CA).
- the IGF-BP3 sequence may be under the control of a constitutive or inducible promoter.
- a constitutive or inducible promoter In the latter instance, one co-administers an inducer.
- Suitable inducible promoters include mouse mammary tumor virus promoter and dexamethasone, metallothionein promoter and zinc, yeast gal 4 promoter and galactose and the like.
- IGF-I plays a role in apoptosis
- inhibition of the IGF-I— IGF-IR axis could sensitize tumor cells to conventional cytotoxic agents or radiation and provide a novel therapeutic approach to cancer treatment.
- a cytotoxic agent or other anti-cancer agent as an additional step in the foregoing methods.
- Suitable cytotoxic agents include paclitaxel, cisplatin, etoposide, paraplatin, bleomycin, plicamycin, doxorubicin, dimethyl triazeno imidazole carboxamide (DTIC), daunorubicin, cytarabine, procarbazine, 1-
- CCNU ⁇ -chloroethyl-l-nitrosourea
- BCNU 1 ,3-bis ( ⁇ -chloroethyl)-l- nitrosourea
- vincristine vinblastine
- o,p'-dichloro-diphenyldichloroethane o,p'-DDD
- mitotane cyclophosphamide
- ifosfamide a cyclophosphamide derivative
- 5-fluorouracil busulfan
- dactinomycin mitomycin-C
- 6-thioguanine thio-TEPA
- chloroambucil 6- mercaptopurine
- methotrexate nitrogen mustard, and the like.
- Suitable anti-cancer agents include interferon, tamoxifen, testolactone, L-asparaginase, progesterone (megace, megestrol acetate), prednisone, androgens, estrogens, and the like.
- progesterone megace, megestrol acetate
- prednisone androgens, estrogens, and the like.
- cytotoxics and other anti-cancer agents are listed in the Food and Drug Administration's "Orange Book," i.e., Approved Drug Products with Therapeutic Equivalence Evaluations, U.S. Dept. of Health and Human Services (1994), and its 1995 supplements.
- the invention further concerns methods of identifying substances useful in treatment of p53-related tumors.
- One such method involves introducing into a host cell (e.g., by transfection) a construct having either or both of Box A and Box B (SEQ. ID. NOS.: 2 and 3) operatively linked to a reporter gene.
- a construct having either or both of Box A and Box B (SEQ. ID. NOS.: 2 and 3) operatively linked to a reporter gene.
- the term "operatively linked” means that the regulatory DNA sequences (SEQ. ID. NOS.: 2 and 3) are capable of increasing the expression of the RNA encoded by the reporter gene.
- the regulatory sequences may be upstream of the coding region, downstream, or in an intron as in the gene for IGF-BP3.
- the reporter gene may be any number of reporters known in the art, such as luciferase, lacZ, chloramphenicol transferase (CAT), and the like.
- test substances that binds to SEQ. ID. NO.: 2 or 3 will upregulate expression of the reporter gene. This method identifies such a substance as an IGF-BP3 modulator that can treat p53-related tumors.
- IGF-BP3 acts by inhibiting IGF-induced DNA synthesis
- This method employs DNA bases (adenosine, thymidine, cytosine, or guanidine) or nucleotides (ATP, GTP, TTP, or CTP) having a detectable label.
- Suitable detectable labels include tritium-labeled thymidine (see Figure 3 and Materials and Methods), 5'-bromo-2'-deoxyuridine and the like.
- one treats a cell with the labeled compound, a test substance, and IGF-I or IGF-II.
- IGF-I and IGF-II include recombinant variants thereof such as those supplied by UBI.
- Another method identifies compounds that mimic IGF-BP3 activity (e.g., by inhibiting binding of IGF to IGFR).
- one treats cells or cell membrane preparations comprising IGFR with detectably labeled IGF (e.g., radioiodinated IGF) and detects binding of the detectable label.
- IGF e.g., radioiodinated IGF
- This method can employ, for example, CHO cells that include IGFR or cell membrane preparations therefrom.
- Ligand binding assays are well known in the art; see, for example, Steele-Perkins et aj. (1988), J. Biol. Chem. 263: 11486-92.
- EB-1 colon carcinoma cells served as a model system to identify novel p53-induced target genes encoding potential mediators of p53 tumor suppression. These cells carry an inducible wild type p53 transgene under the control of the metallothionein promoter and undergo apoptosis upon induction of p53 by metal ions. Shaw et aL (1992), Proc. Natl. Acad. Sd USA 89: 4495-9. We used a subtractive cDNA cloning approach (see Figure 1 and
- FIG. 1a shows schematically the structure of the IGF-BP3 gene reported in Cubbage et aL (1990), as well as the location and sequence of the isolated cDNA fragment (probe V9). This fragment maps to the 3' untranslated region within exon 5.
- Figure 1b shows a northem blot analysis of CdCl2-induced EB-1 cells using radiolabeled probe V9 to monitor IGF-BP3 mRNA expression.
- FIG. 10640-4 shows a northem blot analysis of IGF-BP3 mRNA expression in clonal Saos -2-D4H cells. These cells carry an inducible, temperature-sensitive transgene encoding mutant human p53V143A (described in detail in Buckbinder et aL (1994)). With tetracycline absent from the cell culture medium, the cells express high levels of p53V143A protein.
- Figure 1d shows a kinetic analysis of p53-mediated induction of IGF-BP3 mRNA expression in EB-1 cells. Compared to the increase in p21 and hdm-2 mRNA levels, induction of IGF-BP3 mRNA is somewhat delayed, increasing 4 to 8 hours after CdU2-stimulation. This raises the question whether the increase in IGF-BP3 gene expression represents a direct p53-response.
- FIG. 2c shows that both Box A and Box B DNA confer wild type specific p53-inducibility to a heterologous promoter when introduced into human Saos-2 cells, confirming the nature of these DNA sequences as p53-responsive elements. Consistent with the DNA binding studies, Box A confers considerably stronger induction by p53 than Box B. However, two copies of Box B DNA confer increased sensitivity to p53, indicating that Box B DNA, in cooperation with Box A DNA, could potentially contribute to a p53-dependent induction of IGF-BP3 gene transcription. p53's induction of IGF-BP3 gene expression is significant because IGF-BP3 binds IGF-I and -II.
- IGF-BP3 reduces the availability of free IGFs and thus regulates their proliferative and mitogenic effects.
- p53- induced and recombinant IGF-BP3 inhibits IGF-l-induced DNA synthesis in Saos-2 osteosarcoma cells ( Figures 3a, 3b, and 3c).
- IGF-I and IGF-II act as autocrine and paracrine growth factors in adult tissues, affecting both normal and abnormal growth.
- the IGF-I/IGF-IR axis has been particularly well characterized. Loss of IGF-I and/or IGF-IR function is associated with:
- IGF-I protects cells from c-m c-induced, p53- dependent apoptosis. Hermeking. & Eick (1994), Science 265: 2091 -3; and Harrington et aL (1994), EMBO J. 13: 3286-95. Thus, IGF-I can act as a survival factor and may have a more accentuated role in oncogene-driven cells than in normal cells.
- IGF-BP3 plays an important autocrine and paracrine role in growth control by modulating IGFs-regulated processes. This role is especially significant because IGF-BP3 is expressed in multiple adult human tissues ( Figure 4a).
- IGF-BP3 inhibits IGF-l-induced DNA synthesis ( Figure 3).
- IGF-BP3 expression is upregulated in quiescent and senescent cells (Moerman et aL (1993_ Exp. Geronotol. 28: 361-70: and Grigoriev et al. (1994). J. Cell. Physiol. 160: 203-11 ).
- IGF-BP3 expression is upregulated upon growth arrest of estradiol-dependent breast cancer cells. Pratt et al. (1993). Cancer Res. 53: 5193-8.
- IGF-BP3 may regulate apoptosis by inhibiting IGF-I from acting as a survival factor.
- IGF-BP3 links p53 to the IGF-I(II)/IGFR axis, providing insights into potential novel mechanisms whereby p53 may regulate cellular growth and apoptosis.
- IGF-BP3 IGF-BP3 regulation of IGF-BP3 gene expression by wild type p53
- Figure 1 We treated parental EB and clonal EB-1 cells with or without CdCl2 (6 ⁇ M) for 10 hours.
- luciferase reporter constructs For Figure 2c, we co-transfected luciferase reporter constructs with expression constructs encoding wt p53 or mutant p53V143A, or vector pcDNA, respectively.
- the luciferase constructs had either one copy of Box A, one or two copies of Box B, or multiple copies of the bacterial tet repressor binding site (pUHC13-3).
- pUHC13-3 bacterial tet repressor binding site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96930842A EP0871475A2 (en) | 1995-09-14 | 1996-09-12 | Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors |
JP9512100A JP2000502322A (en) | 1995-09-14 | 1996-09-12 | Insulin-like growth factor binding protein 3 (IGF-BP3) in the treatment of P53-related tumors |
IL12338396A IL123383A0 (en) | 1995-09-14 | 1996-09-12 | Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors |
CA002232000A CA2232000A1 (en) | 1995-09-14 | 1996-09-12 | Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors |
AU69752/96A AU718451B2 (en) | 1995-09-14 | 1996-09-12 | Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors |
MXPA/A/1998/001704A MXPA98001704A (en) | 1995-09-14 | 1998-03-03 | Protein 3 linkage to the insulin-like growth factor (igf-bp3) in the treatment of tumors related to |
NO981127A NO981127L (en) | 1995-09-14 | 1998-03-13 | Insulin-like growth factor binding protein3 (JGF_BP3) in the treatment of P-53 related tumors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US373095P | 1995-09-14 | 1995-09-14 | |
US60/003,730 | 1995-09-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997009998A2 true WO1997009998A2 (en) | 1997-03-20 |
WO1997009998A3 WO1997009998A3 (en) | 1997-04-10 |
Family
ID=21707302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/014623 WO1997009998A2 (en) | 1995-09-14 | 1996-09-12 | Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors |
Country Status (8)
Country | Link |
---|---|
US (1) | US5840673A (en) |
EP (1) | EP0871475A2 (en) |
JP (1) | JP2000502322A (en) |
AU (1) | AU718451B2 (en) |
CA (1) | CA2232000A1 (en) |
IL (1) | IL123383A0 (en) |
NO (1) | NO981127L (en) |
WO (1) | WO1997009998A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006017824A2 (en) * | 2004-08-06 | 2006-02-16 | The Trustees Of Columbia University In The City Of New York | Igf-bp3-related methods for inhibiting tumor growth |
US7192738B2 (en) | 2003-10-03 | 2007-03-20 | Genentech, Inc. | IGF binding proteins |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6020135A (en) * | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
WO2000041730A1 (en) | 1999-01-13 | 2000-07-20 | Meditech Research Limited | A composition and method for the enhancement of the efficacy of drugs |
AU3579200A (en) * | 1999-02-26 | 2000-09-14 | Saltech I Goteborg Ab | Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1 |
EP1290162A4 (en) * | 2000-05-17 | 2005-08-17 | Univ Oregon Health Sciences | Induction of apoptosis and cell growth inhibition by protein 4.33 |
AUPQ879500A0 (en) * | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
US9066919B2 (en) * | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
AU2001291090B2 (en) * | 2000-09-19 | 2007-05-10 | Bioexpertise, Llc | Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
US20050042303A1 (en) * | 2001-08-27 | 2005-02-24 | Brown Tracey Jean | Therapeutic protocols |
US6914049B2 (en) | 2001-09-18 | 2005-07-05 | Bioexpertise, Llc | IGF-binding protein-derived peptide or small molecule |
US6887851B2 (en) * | 2001-09-18 | 2005-05-03 | Bioexpertise, Llc | IGF-binding protein-derived peptide |
EP1435986B1 (en) * | 2001-09-18 | 2008-01-02 | Bioexpertise, Llc | Igf-binding protein-derived peptide |
WO2003068160A2 (en) * | 2002-02-13 | 2003-08-21 | The Trustees Of Columbia University In The City Of New York | Use of insulin-like growth factor binding protein 3 (igf-bp3) for inhibition of tumor growth |
US20040005294A1 (en) * | 2002-02-25 | 2004-01-08 | Ho-Young Lee | IGFBP-3 in the diagnosis and treatment of cancer |
WO2004111262A1 (en) * | 2003-06-18 | 2004-12-23 | Pharmacia & Upjohn Company Llc | Method of identifying a selective chemotherapeutic agent |
JPWO2006070577A1 (en) * | 2004-12-28 | 2008-06-12 | 独立行政法人海洋研究開発機構 | Floating float and how to use it |
EP1912658B1 (en) * | 2005-07-27 | 2017-01-25 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
CN101287475B (en) * | 2005-09-07 | 2012-11-14 | 阿尔卡米亚肿瘤学股份有限公司 | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004030A1 (en) * | 1992-08-26 | 1994-03-03 | Celtrix Pharmaceuticals, Inc. | Method for systemic treatment of catabolic conditions and systemic tissue injury |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5573925A (en) * | 1994-11-28 | 1996-11-12 | The Wistar Institute Of Anatomy And Biology | P53 proteins with altered tetramerization domains |
-
1996
- 1996-09-12 IL IL12338396A patent/IL123383A0/en unknown
- 1996-09-12 US US08/713,052 patent/US5840673A/en not_active Expired - Lifetime
- 1996-09-12 EP EP96930842A patent/EP0871475A2/en not_active Ceased
- 1996-09-12 CA CA002232000A patent/CA2232000A1/en not_active Abandoned
- 1996-09-12 WO PCT/US1996/014623 patent/WO1997009998A2/en not_active Application Discontinuation
- 1996-09-12 AU AU69752/96A patent/AU718451B2/en not_active Ceased
- 1996-09-12 JP JP9512100A patent/JP2000502322A/en active Pending
-
1998
- 1998-03-13 NO NO981127A patent/NO981127L/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004030A1 (en) * | 1992-08-26 | 1994-03-03 | Celtrix Pharmaceuticals, Inc. | Method for systemic treatment of catabolic conditions and systemic tissue injury |
Non-Patent Citations (5)
Title |
---|
EUR. J. ENDOCRINOL. (1996), 134(4), 426-427, 1996, XP000644664 BERTHERAT, JEROME: "Insulin-like growth factor binding protein 3 ( IGFBP -3): a novel target of the tumor suppressor p53 inhibiting cell growth" * |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 21, 15 July 1990, MD US, pages 12642-12649, XP002025926 CUBBAGE M.L. ET AL.: "Insulin-like Growth Factor Binding protein-3" cited in the application * |
MOLECULAR AND CELLULAR BIOLOGY 16 (9). 1996. 4952-4960, XP000644678 LUDWIG R L ET AL: "Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function." * |
NATURE (LONDON) 377 (6550). 1995. 646-649, XP002025927 BUCKBINDER L ET AL: "Induction of the growth inhibitor IGF - binding protein 3 by p53." * |
PROGRESS IN GROWTH FACTOR RESEARCH, vol. 6, no. 2-4, 1995, pages 503-512, XP000644670 OH Y. ET AL.: "Antiproliferative actions of insuline-like growth factor binding protein (IGFBP)-3 in human breast cancer cells" * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192738B2 (en) | 2003-10-03 | 2007-03-20 | Genentech, Inc. | IGF binding proteins |
US7348154B2 (en) | 2003-10-03 | 2008-03-25 | Genentech, Inc. | IGF binding proteins |
US7351545B2 (en) | 2003-10-03 | 2008-04-01 | Genentech, Inc. | IGF binding proteins |
WO2006017824A2 (en) * | 2004-08-06 | 2006-02-16 | The Trustees Of Columbia University In The City Of New York | Igf-bp3-related methods for inhibiting tumor growth |
WO2006017824A3 (en) * | 2004-08-06 | 2007-01-04 | Univ Columbia | Igf-bp3-related methods for inhibiting tumor growth |
Also Published As
Publication number | Publication date |
---|---|
JP2000502322A (en) | 2000-02-29 |
US5840673A (en) | 1998-11-24 |
NO981127D0 (en) | 1998-03-13 |
AU6975296A (en) | 1997-04-01 |
MX9801704A (en) | 1998-05-31 |
WO1997009998A3 (en) | 1997-04-10 |
AU718451B2 (en) | 2000-04-13 |
EP0871475A2 (en) | 1998-10-21 |
NO981127L (en) | 1998-03-13 |
IL123383A0 (en) | 1998-09-24 |
CA2232000A1 (en) | 1997-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU718451B2 (en) | Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors | |
Kaulsay et al. | Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone | |
Werner et al. | Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. | |
Buckbinder et al. | Induction of the growth inhibitor IGF-binding protein 3 by p53 | |
Kang et al. | A self-enabling TGFβ response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells | |
Zhang et al. | Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation | |
Gloudemans et al. | Insulin-like growth factor gene expression in human smooth muscle tumors | |
Oetjen et al. | Distinct properties of the cAMP-responsive element of the rat insulin I gene. | |
Ayalon et al. | Transcriptional regulation of IGF-I receptor gene expression by the PAX3–FKHR oncoprotein | |
Slootweg et al. | Estrogen enhances growth hormone receptor expression and growth hormone action in rat osteosarcoma cells and human osteoblast-like cells | |
US20030109537A1 (en) | Methods and materials for treating bone conditions | |
AU2021225180A1 (en) | Methods for identification, assessment, prevention, and treatment of metabolic disorders using Slit2 | |
Giannini et al. | HMGI (Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness | |
Matsumoto et al. | Retinoic acid regulates insulin-like growth factor II expression in a neuroblastoma cell line. | |
Hou et al. | The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells | |
Patti et al. | Autocrine secreted insulin-like growth factor-I stimulates MAP kinase-dependent mitogenic effects in human primitive neuroectodermal tumor/medulloblastoma. | |
Taschner et al. | Ca2+/Calmodulin-dependent kinase II signaling causes skeletal overgrowth and premature chondrocyte maturation | |
Quinn et al. | Ligand‐dependent inhibition of myoblast differentiation by overexpression of the type‐1 insulin‐like growth factor receptor | |
MXPA98001704A (en) | Protein 3 linkage to the insulin-like growth factor (igf-bp3) in the treatment of tumors related to | |
Kim et al. | Down‐regulation of insulin‐like growth factor binding proteins and growth modulation in hepatoma cells by retinoic acid | |
Miao et al. | SOCS3 suppresses AP-1 transcriptional activity in neuroblastoma cells through inhibition of c-Jun N-terminal kinase | |
EP0969100A1 (en) | Method for screening heat shock protein expression induction regulators | |
Su et al. | Mouse keratinocytes express c98, a novel gene homologous to bcl-2, that is stimulated by insulin-like growth factor 1 and prevents dexamethasone-induced apoptosis | |
Halter et al. | Pretreatment with vitamin A inhibits transforming growth factor alpha stimulation of human mammary carcinoma cells | |
US20030124554A1 (en) | Screening method for compounds capable of modularing egr-1-regulated expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA IL JP MX NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/001704 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 512100 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2232000 Country of ref document: CA Ref country code: CA Ref document number: 2232000 Kind code of ref document: A Format of ref document f/p: F |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996930842 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996930842 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1996930842 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996930842 Country of ref document: EP |